Search

Displaying results 4281 - 4290 of 9670 in total
  1. Drug

    Carbarsone

    go.drugbank.com/drugs/DB11382
    ExperimentalVet approved

    It belongs to the _organoarsenic_ group of chemical compounds and has antiamebic properties. … It is also used as a food additive with the goal of increasing weight gain and controlling the occurrence of blackhead disease in chicken and turkeys.

  2. Drug

    Osanetant

    go.drugbank.com/drugs/DB04872
    Investigational

    In a review of its R&D portfolio, the company announced in August 2005 that it would cease any further development of osanetant. … Developed by Sanofi-Aventis (formerly Sanofi-Synthelabo), osanetant (SR-142801) is an NK3 receptor antagonist which was under development for the treatment of schizophrenia and other Central Nervous System

  3. Drug

    CRx-119

    go.drugbank.com/drugs/DB05688
    Experimental

    CRx-119 is a novel synergistic combination drug candidate discovered using the CombinatoRx combination High Throughput Screening (cHTS(TM)) technology with potential therapeutic use in a broad range of immuno-inflammatory conditions. CRx...

  4. Drug

    P54

    go.drugbank.com/drugs/DB05451
    Experimental

    It inhibits the induction of the enzyme NFkB, thereby inhibiting downstream inflammatory genes such as COX II and iNOS.

  5. Drug

    Chlorophyll B

    go.drugbank.com/drugs/DB04506
    Experimental

    It has the atomic symbol Mg, atomic number 12, and atomic weight 24.31. … (From Dorland, 27th ed)

  6. Drug

    Diacetyl benzoyl lathyrol

    go.drugbank.com/drugs/DB11260
    Approved

    It is also reported to be a skin conditioning agent.

  7. Drug

    Drinabant

    go.drugbank.com/drugs/DB05750
    Investigational

    AVE-1625 is an oral selective and potent antagonist of cannabinoid 1 (CB1) receptors having the same mechanism of action as rimonabant. … It is currently developed in obesity and its associated comorbidities. AVE-1625 is also being developed for the treatment of Alzheimer disease.

  8. Drug

    Scorpion (centruroides) immune Fab2 antivenin (equine)

    go.drugbank.com/drugs/DB13905
    Approved

    It was approved by FDA in 2011 and is marketed under the name Anascorp [L2196]. Anascorp is produced from equine IgG antibodies. … It is intravenously administered patients with clinical signs of scorpion envenomation so that the Fab fragments bind to the toxins and limit systemic toxicity.

  9. Drug

    Laquinimod

    go.drugbank.com/drugs/DB06685
    Investigational

    It has been shown to reduce disease activity on magnetic resonance imaging and to be well tolerated orally. … It is currently under development in phase III trials for treatment of multiple sclerosis as an oral therapy, like fingolimod.

  10. Drug

    Honey

    go.drugbank.com/drugs/DB14242
    ApprovedInvestigational

    It is not an approved drug.